DNA05 Argenx_ARGX-113-2308: A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab)
Clinical Trial Grant
Administered By
School of Medicine
Awarded By
Argenx BVBA
Start Date
October 24, 2024
End Date
December 1, 2029
Administered By
School of Medicine
Awarded By
Argenx BVBA
Start Date
October 24, 2024
End Date
December 1, 2029